2021 All pharmaceutical companies have to sign this Promise.

In fact, after New Year's Day, Anhui, Yunnan and other provinces have issued similar notices, requiring pharmaceutical companies, consumables enterprises, pharmaceutical businesses involved in the procurement of provincial platforms to submit "pharmaceutical enterprises price and marketing behavior credit commitment."
for the time, other provinces and cities also have corresponding requirements.
For example, Shanghai's notice states that the deadline is March 31, anhui Province's request is to complete the submission of the e-version commitment by January 29, 2021, taking into account the normal outbreak prevention and control, the electronic version of the commitment to submit, no longer need to submit a paper commitment.
Yunnan Province requires that by the end of February 2021, the proportion of written commitments submitted by bidding enterprises should reach more than 80%, and by the end of March 2021, it will reach more than 95%.
to the submission of pharmaceutical enterprises in a timely manner, Yunnan Provincial Government Procurement and Delivery Center will be announced to remind, and do a good job of detailed records, as the basis for follow-up processing.
Both Shanghai and Yunnan provinces require pharmaceutical companies that have not submitted written commitments to no longer accept their new tenders or applications for online registration as of April 1, 2021, and from June 1, 2021, their winning or registered pharmaceutical products should be removed from the network if other enterprises guarantee supply or have alternatives to meet their clinical needs.
this is consistent with the NHS's request at the end of last month, which will be mentioned later.
in general, this year pharmaceutical companies if they want to sell in China, this commitment must be signed.
system has been brewing for a long time, 2021 landing implementation we should realize that in the drug national collection and regional collection at the same time, information exchange, drug prices fall, the credit commitment to pharmaceutical companies is naturally regarded as an important goal at the time.
For this "Pharmaceutical Enterprise Price and Marketing Behavior Credit Commitment", the National Health Insurance Administration has been preparing as early as 2019, after Sharing, december 6, 2019, the National Health Insurance Administration issued the "Opinion on doing a good job in the current management of drug prices" (Medicare Issue 2019) 67) notice, on the management of drug prices put forward a number of views, which mentioned the exploration of the establishment of trustworthy incentives and bad faith disciplinary mechanism, combined with the price recruitment credit evaluation system construction, timely disclosure of drug operators price information (see MRCLUB historical news: everyone concerned about the "drug price" issue, the National Health Insurance Administration issued a letter! ）。
March 5, 2020, in the State Council's Opinion on Deepening the Reform of the Health Care System, the establishment of a system of evaluation of drug prices and credit ratings was again mentioned (see MRCLUB Historical News: Heavy Policy!). National health insurance drug use unified, the full implementation of volume procurement, promote the one-vote system ... ）。
In September last year, official documents were released, and on September 16th the National Health Insurance Administration officially issued the Guidance on the Establishment of a Credit Evaluation System for Pharmaceutical Prices and Recruitment, two of which attracted the attention of the industry: First, the establishment of a catalogue of medical prices and recruitment of unreliable matters, The implementation of dynamic adjustment, listed in the list of breach of trust mainly includes the pharmaceutical purchase and sale of rebates or other improper benefits (referred to as "pharmaceutical commercial bribery"), tax-related violations, the implementation of monopoly acts, improper price behavior, disrupt the centralized procurement order, malicious breach of contract agreements and other acts contrary to good faith.
The second is to implement the active commitment system of pharmaceutical enterprises, requiring pharmaceutical enterprises to participate in or entrust to participate in centralized procurement of pharmaceutical and medical supplies, platform networking, as well as public medical institutions and non-public medical institutions designated for medical insurance for the record procurement, should be in the name of an independent legal person to the relevant drugs and medical consumption The centralized purchasing agency submits a written commitment, which includes establishing a compliance review system, putting an end to the misconduct, regulating the sales of its own medicines or medical supplies by its employees (including employment relations) or distribution enterprises with a principal-agent relationship, assuming corresponding liability for failure of trust, accepting disposal measures, etc.
Built so that pharmaceutical enterprises "dare not, can not, do not want" to give rebates to the governance system needs a multi-pity phased efforts, in order to introduce the system, in the past year, we can also see that in addition to the Introduction of the National Health Insurance Bureau and other institutions, the relevant state agencies have also carried out corresponding treatment of individual enterprises, and make reports, hoping to cause the enterprise's alarm.
In the past, it was a fact that some pharmaceutical companies were often insensitive to fines in kickback cases, but in the context of national mining, giving kickbacks would lead to the loss of access to the centralized procurement market, which would have a powerful deterrent effect, thus forming an effective system of governance.
deadline: April 1st! On the 25th of last month, the State Health Insurance Administration again issued the Notice on Speeding Up the Implementation of the Medical Price and Credit Evaluation System, which requires that the signing of commitments be a top priority at this stage, and that the proportion of written commitments submitted by bidding enterprises should reach more than 80% by the end of February 2021 and more than 95% by the end of March 2021.
the submission is not timely, the provincial centralized procurement agencies should promptly remind the time limit requirements, inform the relevant impact, do a good job of detailed records, as the basis for follow-up processing.
For those who have not submitted a written commitment, as of April 1, 2021, provincial centralized purchasing agencies will no longer accept their new tenders or applications for the internet;
, and the NHS is demanding that this work be made as quickly as possible! The requirements are as follows: "The provincial centralized procurement agencies, in accordance with the principle of territory, pay close attention to the local courts, taxation, market supervision and other departments of the public decision on adjudication documents, administrative penalties, especially the media focused on the typical case, timely correspondence to investigate the enterprises involved, require enterprises to explain the situation, supplement the information required to deal with the case, if necessary, ask the relevant departments to give the source information support, in accordance with the requirements of the system, as soon as possible in the credit rating, graded disposal of substantive governance results."
" it is understood that since this month, the National Health Insurance Administration has set up a dispatch mechanism to start tracking the progress of local recruitment agencies for this work, as well as the handling of typical cases.
punish a business for losing faith? See here, small partners should be more concerned about the issue is, signed a commitment, if the enterprise lost faith, how to punish? Dami also briefly introduced here, on November 20 last year, the National Health Insurance Administration has issued the "Pharmaceutical Price and Credit Rating Discretionary Benchmark (2020 Edition)", for "pharmaceutical enterprise prices or marketing behavior" of the disrepair rating is divided into four levels: general, medium, serious, particularly serious.
For example, according to the facts of the case determined by the court judgment or the administrative punishment of the relevant law enforcement departments, in the past three years, various medical institutions at all levels, centralized procurement agencies and their staff have been given kickbacks and other medical commercial bribery, the level of failure of trust is divided as such: "particularly serious: the same case accumulated or a single bribe amount of more than 2 million yuan, this kind of behavior is "particularly serious."
serious: in the same case, the cumulative amount of bribes of more than 500,000 yuan, less than 2 million yuan, or a single bribe amount of more than 300,000 yuan, less than 2 million yuan.
: in the same case, the cumulative amount of bribes of more than 150,000 yuan, less than 500,000 yuan, or a single bribe amount of more than 100,000 yuan, less than 300,000 yuan.
General: in the same case, the cumulative amount of bribes of more than 10,000 yuan (including 10,000 yuan), less than 150,000 yuan (excluding 150,000 yuan), or a single bribe amount of more than 10,000 yuan, less than 100,000 yuan.